Individuals with metastatic breast cancer could soon have access to personalized, supplemental supportive care through their smart speaker, thanks to new research at Penn State.
Surgery, in addition to treatments like chemotherapy and radiation therapy, may increase the length of survival for metastatic breast cancer patients, according to Penn State College of Medicine and Penn State Cancer Institute researchers
Ongoing updates are underway for NCCN Guidelines for Breast Cancer in Chinese, English, French, Japanese, Korean, Spanish, Polish, and Portuguese, free online at NCCN.org/global. Follow #NCCNGlobal for more. The NCCN Foundation is hosting free metastatic breast cancer webinars for patients and caregivers on October 8 and 12 at NCCN.org/patients.
New data from the Phase III EMBRACA trial led by researchers at The University of Texas MD Anderson Cancer Center found the PARP inhibitor talazoparib did not demonstrate a statistically significant overall survival (OS) benefit for patients with metastatic HER2-negative breast cancer and mutations in the BRCA1/2 genes. Most patients included in the study went on to receive subsequent systemic therapies, which may have affected the survival outcome analysis. The research confirmed previous results showing talazoparib improved patient reported quality-of-life measures over available chemotherapies and had a tolerable safety profile.
The National Comprehensive Cancer Network® (NCCN®) Oncology Research Program (ORP) announces proposals selected for funding, in collaboration with Pfizer Global Medical Grants, to improve the quality of care and outcomes for people with metastatic breast cancer (MBC).
Mayo Clinic will host the Sixth Annual Metastatic Breast Cancer Conference at the Omni Scottsdale Resort and Spa at Montelucia in Scottsdale, Arizona, Sept. 19–20. This program is a joint effort among Mayo Clinic, Baylor College of Medicine, and Theresa’s…